Floating and Swelling Characteristics of Various Excipients Used in Controlled Release Technology

Gerogiannis, V. S.; Rekkas, Dimitrios M.; Dallas, Paraskevas; Choulis, N.H.

doi:10.3109/03639049309063001

Cited by 34 publications

(18 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be explained by the fact that sodium bicarbonate present in the formulation as an insoluble dispersion becomes soluble in the acidic medium provided by citric acid, and released Na + which reacted with the polymer and produced a cross-linked three-dimensional gel network [14]. Thus the trapped gas increases the duration of floating time.…”

Section: Discussionmentioning

confidence: 99%

Design and Evaluation of an Oral Floating Matrix Tablet of Salbutamol Sulphate

Kumar¹,

Sahu²,

Sharma³

et al. 2012

Trop. J. Pharm Res

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Design and Evaluation of an Oral Floating Matrix Tablet of Salbutamol Sulphate

Kumar¹,

Sahu²,

Sharma³

et al. 2012

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…Designed 9 batches were also analyzed for response Y 2 , and values were presented in Table 3. The results of Table 3 revealed that formulation F1 (OBM only used as polymer) exhibited 6.5 h of t 90% , and on the other hand, formulation F7 (HPMC K100M only used as polymer) showed 8 h. This confirmed the highest drug release retarding property of HPMC K100M than OBM.…”

Section: Time Taken For 90% Drug Release -T 90% (Y 2 )mentioning

confidence: 99%

“…This is evidenced by extensive research work that has been conducting since 1990's to till date. [2][3][4] In addition to this, recently, many researchers have been developing GRFDDS by optimization technique which utilizes optimum concentrations of combination of polymers to get product with desirable qualities. [5][6][7][8][9][10] This optimization technique provides the study of factors in all possible combinations with minimum experimentation and time [11] based on the design expert software, response surface methodology (RSM) graphs.…”

Section: Introductionmentioning

confidence: 99%

Untitled

Prasanthi¹

2017

AJP

View full text Add to dashboard Cite

Aim: The present study aimed at the development of valsartan floating tablets (VFTs) using Ocimum basilicum mucilage (OBM) and hydroxypropyl methylcellulose (HPMC) K100M by applying response surface methodologybased 3 2 factorial design. Materials and Methods: OBM (A) and HPMC K100M (B) were selected as independent factors, and swelling index (Y 1 ) and time taken for 90% drug release (Y 2 ) were as responses. Experimentally designed 9 runs assessed for Y 1 and Y 2 , and analysis of variance (ANOVA) was applied (P < 0.05) to define significant terms. Multicriterion decision approach anticipated optimized formulation VFT was developed and evaluated for physicochemical parameters such as weight variation, hardness, friability, thickness, and drug content. In vitro drug release and buoyancy studies, in vivo buoyancy studies, and Fourier transform infrared (FTIR) studies were carried out along with the validation of experimental design. Results and Discussion: Synergistic effect between polymers was observed in experimental runs, and ANOVA indicated a significant effect of A and B on Y 1 and Y 2 . Physicochemical parameters as well as floating lag time and total floating time of VFT were within the limits. FTIR studies unveiled drug and polymer compatibility. In vitro drug release studies demonstrated a good fit in zero-order and super Case-II transport drug release mechanism. Experimental values of VFT exhibited good agreement with predicted values generated by the software. In vivo buoyancy study in rabbit confirmed floatability of the VFT for 12 h. Conclusion: The present investigation concluded that statistically optimized VFT with OBM and HPMC K100M as rate retarding polymers exploiting as a promising formulation for gastric delivery of valsartan for longer periods.

show abstract

“…Need of gastroretention arises because of reason of improve the bioavailability of drugs such as cyclosporine, ciprofloxacin, ranitidine, metoprolol tartrate, and cefuroxime axetil which are mainly absorbed from the upper part of GIT or get degraded in alkaline PH. [15,16] To improve the bioavailability of drugs such as cyclosporine, ciprofloxacin, ranitidine, metoprolol tartrate, and cefuroxime axetil which are mainly absorbed from the upper part of GIT or get degraded in alkaline P H .…”

Section: Gastroretentive Dosage Form (Grdf)mentioning

confidence: 99%

“…Anatomy [16][17][18] Anatomically, the stomach is divided into three regions: Fundus, body, and antrum (pylorus). The distal part made of fundus and body acts as a reservoir for nondigested material, whereas the antrum is acted as a pump for gastric emptying by propelling actions and the major site for mixing motions.…”

Section: Basic Gitmentioning

confidence: 99%

Untitled

Katiyar

2017

AJP

View full text Add to dashboard Cite

Floating drug delivery systems (FDDS) are controlled release drug delivery systems, which get retained in the stomach for longer periods, thus helping in absorption of drug for the intended duration of time. Gastricretentive drug delivery devices can be useful for the spatial and temporal delivery of many drugs. In general, drugs with narrow therapeutic window and prone to degradation in intestine and colon along with drugs having low retention time in gastrointestinal tract (GIT) are selected for FDDS which helps drugs to stay long time in stomach thus increasing gastric residence time and reduces dosing frequency. The present review article shows the various methods of FDDS for increasing retention time of drugs in GIT.

show abstract

Floating and Swelling Characteristics of Various Excipients Used in Controlled Release Technology

Cited by 34 publications

References 3 publications

Design and Evaluation of an Oral Floating Matrix Tablet of Salbutamol Sulphate

Design and Evaluation of an Oral Floating Matrix Tablet of Salbutamol Sulphate

Untitled

Untitled

Contact Info

Product

Resources

About